Conditional transgenic technologies.
Transgenic technology has been revolutionised by the development of techniques that allow temporo-spatial control of gene deletion or expression in transgenic animals. The ability to switch gene expression 'on' or 'off' in restricted tissues at specific times allows unprecedented flexibility for exploring gene function in both health and disease. As use of these techniques grows in all areas of biomedical research, an understanding of this topic is essential. In this review we examine the theory, application and limitations of these strategies, with particular reference to endocrine research.
Ryding
A D
AD
Molecular Physiology Group, University of Edinburgh Medical School, Wilkie Building, Teviot Place, Edinburgh EH8 9AG, UK. alisdair.ryding@ed.ac.uk
Sharp
M G
MG
Mullins
J J
JJ
D000818:Animals; D001426:Bacterial Proteins / Q000235:genetics; D001921:Brain / Q000378:metabolism; D001947:Breeding; D019363:Cytochrome P-450 CYP1A1 / Q000378:metabolism; D004440:Ecdysone / Q000494:pharmacology; D004704:Endocrinology / Q000379:methods*; D004790:Enzyme Induction; D017353:Gene Deletion; D015870:Gene Expression / Q000187:drug effects; D015971:Gene Expression Regulation, Enzymologic; D018014:Gene Transfer Techniques; D006801:Humans; D019426:Integrases / Q000235:genetics; D008099:Liver / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D023421:Models, Animal; D016297:Mutagenesis, Site-Directed; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D011995:Recombination, Genetic; D012106:Research; D013234:Stem Cells / Q000378:metabolism; D013752:Tetracycline / Q000494:pharmacology; D014764:Viral Proteins / Q000235:genetics
D001426:Bacterial Proteins; D011500:Protein Synthesis Inhibitors; D014764:Viral Proteins; D004440:Ecdysone; D019363:Cytochrome P-450 CYP1A1; C045073:Cre recombinase; D019426:Integrases; D013752:Tetracycline